Hall serves as director of regulatory s1cience, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, at the U.S. Food and Drug Administration. In this role, she leads post-market drug safety activities focused on adverse event signal detection and characterization. She also leads pharmacoepidemiology research programs, pharmacovigilance innovative tool development efforts, and regulatory science policy initiatives to support post-market drug safety.
Prior to being selected as director of regulatory science, Hall served as program director for regulatory research in the Office of Surveillance and Epidemiology, and as senior analyst conducting strategic planning for translational sciences and for data standards in the Office of Planning and Informatics.
Before joining the FDA in 2008, Hall was a program director at Pfizer, in the Public Health Group of External Medical Affairs. She continues to lecture at Columbia University’s Mailman School of Public Health, where she has been an adjunct professor since 2007. Hall holds a bachelor’s degree in chemistry and in society, technology, and policy from WPI, a master’s in public health from Columbia University’s Mailman School of Public Health, and a master’s in biochemistry and a PhD in toxicology from Columbia University’s Graduate School of Arts and Sciences.
